vs
Side-by-side financial comparison of Maison Solutions Inc. (MSS) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
Maison Solutions Inc. is the larger business by last-quarter revenue ($27.6M vs $19.1M, roughly 1.4× NewAmsterdam Pharma Co N.V.). Maison Solutions Inc. runs the higher net margin — -18.0% vs -90.7%, a 72.7% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -10.9%).
Maison Solutions Inc.MSSEarnings & Financial Report
Maison Solutions Inc. is a specialty home goods retail company that provides a diverse portfolio of stylish, affordably priced furniture, home decor items, and daily household products. Its primary market is the Guangdong-Hong Kong-Macao Greater Bay Area in China, serving mass consumers through both offline physical stores and online e-commerce channels.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
MSS vs NAMS — Head-to-Head
Income Statement — Q2 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $19.1M |
| Net Profit | $-5.0M | $-17.4M |
| Gross Margin | 23.4% | — |
| Operating Margin | -4.9% | -186.1% |
| Net Margin | -18.0% | -90.7% |
| Revenue YoY | -10.9% | 740.1% |
| Net Profit YoY | -1840.5% | 55.5% |
| EPS (diluted) | $-0.23 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $27.6M | — | ||
| Q3 25 | $27.2M | — | ||
| Q2 25 | $34.4M | $19.1M | ||
| Q1 25 | $32.3M | — | ||
| Q4 24 | $29.4M | $12.8M | ||
| Q3 24 | $28.2M | $29.1M | ||
| Q2 24 | $16.9M | — | ||
| Q1 24 | $13.6M | — |
| Q4 25 | $-5.0M | — | ||
| Q3 25 | $-1.5M | — | ||
| Q2 25 | $-287.4K | $-17.4M | ||
| Q1 25 | $1.0M | — | ||
| Q4 24 | $-256.0K | $-92.2M | ||
| Q3 24 | $700.9K | $-16.6M | ||
| Q2 24 | $-2.8M | — | ||
| Q1 24 | $-549.0K | — |
| Q4 25 | 23.4% | — | ||
| Q3 25 | 24.1% | — | ||
| Q2 25 | 9.5% | — | ||
| Q1 25 | 21.8% | — | ||
| Q4 24 | 26.9% | — | ||
| Q3 24 | 28.9% | — | ||
| Q2 24 | 13.0% | — | ||
| Q1 24 | 23.4% | — |
| Q4 25 | -4.9% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | -15.9% | -186.1% | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 3.2% | -338.5% | ||
| Q3 24 | 7.3% | -85.9% | ||
| Q2 24 | -14.4% | — | ||
| Q1 24 | -2.3% | — |
| Q4 25 | -18.0% | — | ||
| Q3 25 | -5.7% | — | ||
| Q2 25 | -0.8% | -90.7% | ||
| Q1 25 | 3.1% | — | ||
| Q4 24 | -0.9% | -721.7% | ||
| Q3 24 | 2.5% | -57.2% | ||
| Q2 24 | -16.4% | — | ||
| Q1 24 | -4.0% | — |
| Q4 25 | $-0.23 | — | ||
| Q3 25 | $-0.08 | — | ||
| Q2 25 | $-0.02 | $-0.15 | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $-0.01 | $-0.91 | ||
| Q3 24 | $0.04 | $-0.18 | ||
| Q2 24 | $-0.16 | — | ||
| Q1 24 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $739.2M |
| Total DebtLower is stronger | $2.6M | — |
| Stockholders' EquityBook value | $11.6M | $778.5M |
| Total Assets | $75.4M | $815.1M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $1.1M | — | ||
| Q2 25 | $775.4K | $739.2M | ||
| Q1 25 | $445.4K | — | ||
| Q4 24 | $355.7K | $834.2M | ||
| Q3 24 | $588.9K | $422.7M | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | $9.4M | — |
| Q4 25 | $2.6M | — | ||
| Q3 25 | $2.6M | — | ||
| Q2 25 | $2.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.5M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $2.6M | — |
| Q4 25 | $11.6M | — | ||
| Q3 25 | $10.1M | — | ||
| Q2 25 | $11.7M | $778.5M | ||
| Q1 25 | $12.0M | — | ||
| Q4 24 | $10.9M | $757.5M | ||
| Q3 24 | $11.2M | $378.9M | ||
| Q2 24 | $10.5M | — | ||
| Q1 24 | $13.3M | — |
| Q4 25 | $75.4M | — | ||
| Q3 25 | $73.3M | — | ||
| Q2 25 | $77.4M | $815.1M | ||
| Q1 25 | $82.7M | — | ||
| Q4 24 | $82.7M | $864.6M | ||
| Q3 24 | $82.1M | $439.2M | ||
| Q2 24 | $82.4M | — | ||
| Q1 24 | $44.2M | — |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-37.7M |
| Free Cash FlowOCF − Capex | — | $-37.8M |
| FCF MarginFCF / Revenue | — | -197.2% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | — | ||
| Q3 25 | $1.1M | — | ||
| Q2 25 | $-1.6M | $-37.7M | ||
| Q1 25 | $1.7M | — | ||
| Q4 24 | $1.1M | $-37.5M | ||
| Q3 24 | $3.6M | $-12.5M | ||
| Q2 24 | $-2.6M | — | ||
| Q1 24 | $-1.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-37.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -197.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.66× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.12× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MSS
| Perishables | $14.4M | 52% |
| Nonperishables | $13.2M | 48% |
NAMS
Segment breakdown not available.
